Business Overview

Syndax Pharmaceuticals is a 277-person commercial-stage biopharmaceutical company with two FDA-approved drugs, both approved in 2024, and a pipeline expanding into frontline AML, idiopathic pulmonary fibrosis, and myelofibrosis. It is an asset-light model — zero manufacturing facilities, $181K in PP&E, everything outsourced to contract manufacturers.

Revuforj (revumenib) — first-in-class oral menin inhibitor. Approved for relapsed/refractory acute leukemia with KMT2A translocation (Nov 2024) and R/R NPM1-mutated AML (Oct 2025), in both adults and pediatrics. Syndax owns 100% of US commercialization. FY2025 net revenue: $124.8M. Q4 annualizing ≈$177M and accelerating.

Niktimvo (axatilimab) — first-in-class CSF-1R antibody targeting both fibrosis and inflammation. Approved for chronic graft-versus-host disease after ≥2 prior lines (Aug 2024). Co-commercialized with Incyte under a 50/50 US profit share. FY2025 US net revenue (reported by Incyte): $152M. But Syndax's actual take was $42.4M — 28% of headline, not 50%. The difference: the split is on profits after commercial costs, not on revenue.

The company's total FY2025 revenue was $172.4M: $124.8M Revuforj product revenue + $42.4M Niktimvo collaboration profit share + $5.1M milestones/royalties.

Revenue Architecture: Who Gets What

This is the single most important thing to understand about SNDX, and it's the area most likely to be mismodeled.

Revuforj economics (SNDX keeps ≈83% at steady state):

Net revenue:                          100%
COGS incl. AbbVie royalties:         (5.6% current → 15-17% at steady state)
AbbVie sales milestones:             Up to $70M on annual thresholds
Remaining dev/reg milestones:        ≈$61M

Important nuance: the 10-K states that "cost of product sales includes the cost of goods sold for Revuforj AND license agreement royalties associated with its sales." The reported $7.0M COGS already bundles manufacturing costs and AbbVie royalties together. Current COGS/revenue is 5.6% — artificially low because pre-launch inventory was expensed as R&D and is now being sold at near-zero manufacturing cost. As this inventory depletes and is replaced with $32.8M of full-cost commercial inventory built in 2025, the manufacturing component of COGS will increase. At steady state, COGS (manufacturing + AbbVie royalties combined) should run 15-17% of revenue, yielding ≈83% gross margin. At $200M Revuforj revenue, this is a ≈$15-20M annual gross profit headwind vs the current 94.4% margin that may not be in consensus models.

Niktimvo economics (SNDX keeps ≈28% today, improving toward 30-35%):

Incyte reports US net revenue:        $152M
Less: commercial costs (both sides):  (≈$76M)
US profit (pre-split):               ≈$76M
SNDX 50% share:                      ≈$38M
Plus: cost-sharing offsets:           ≈$4M
SNDX collaboration revenue:          $42.4M  (28% of headline)

Then from SNDX's share:
Less: Royalty Pharma 13.8%:          (≈$5.8M on SNDX's portion)
Less: UCB royalties:                  ("low double-digit %")
Net to SNDX after all obligations:   ≈$32M  (21% effective take)

The 50/50 "profit share" is widely cited but deeply misleading. Syndax captures roughly a fifth of every Niktimvo dollar at current scale. This improves as SG&A is leveraged, but it will never approach 50% of net revenue.

Milestone obligations — the layered burden:

Total milestone outflow exposure exceeds $780M. These accelerate as revenue grows — a tax on success the street may underappreciate.

Addressable Markets

Current penetration of total claimed TAM: <2%.

Financial Profile

Four-Year Arc

The story: losses widened 2022-2024 as the company invested in pivotal trials and built commercial infrastructure. FY2025 is the inflection — first year with meaningful revenue, first year losses narrowed. Revenue grew 7x while OpEx grew 23%.

The financing shift is equally telling. The company raised $172M (2022), $264M (2023), and $353M via the Royalty Pharma deal (2024). In 2025: just $14M from option exercises. Management claims no additional capital is needed to reach profitability.

Balance Sheet

Cash and short-term investments of $394M against total liabilities of $465M, dominated by the Royalty Pharma obligation at ≈$345M carrying value. Stockholders' equity has eroded from $467M to $65M as losses accumulate. Accumulated deficit: $1.51B.

The Royalty Pharma obligation carries a put right: if the UCB license terminates (breach, insolvency, or certain other defaults), Royalty Pharma can force repurchase at the full $822.5M cap. Against $394M in cash, this is a catastrophic tail risk — a balance sheet event that would require immediate dilutive financing or worse. The probability is low (UCB license termination is an extreme scenario), but the magnitude is existential.

Cash Runway and Profitability Path

FY2025 actual:
  Revenue:                      $172M
  Cash OpEx (OpEx - SBC):       ≈$398M
  Operating cash burn:          ($323M)

FY2026E (our estimate):
  Revenue:                      $300-330M (consensus: $363M)
  Cash OpEx (guided):           ≈$350M ($400M - $50M SBC)
  Implied burn:                 ~($20-50M)

FCF breakeven requires:         Revenue > ≈$350M
At 12% QoQ growth from Q4:     FY2026 = $330M → quarterly BE in Q4 2026
At 15% QoQ growth from Q4:     FY2026 = $354M → quarterly BE in Q3 2026
Street consensus ($363M):       Implies ≈13% avg QoQ growth → BE in late 2026

If the revenue trajectory holds, the company reaches operating breakeven by late 2026 or early 2027. But operating breakeven ≠ cash flow breakeven. Working capital consumed ≈$105M in FY2025 ($32.8M inventory build, $30M AR, $43M collaboration receivable). Some of this was one-time (initial inventory build), but AR and collaboration receivables will continue growing with revenue. Assume $30-50M/year working capital drag at scale. True FCF breakeven requires revenue roughly $380-400M, not $350M. If revenue growth stalls below $300M, cash burn resumes at $50-100M/year with $394M remaining.

Tax assets available at profitability: $219M state NOLs, $27M orphan drug credits, $9.8M R&D credits. Federal NOLs of $22.1M begin expiring in 2026 — a minor ticking clock.

Competitive Position

Menin Inhibitors: Revuforj vs Komzifti

This is a two-player market. No other menin inhibitors are near approval. The competitive dynamics split cleanly by indication.

KMT2Ar AML: Monopoly. Revuforj is the only approved therapy. KURA's Komzifti is not approved for KMT2Ar. This represents roughly half the R/R menin inhibitor TAM (≈$1B). Defensible until another menin inhibitor gets a KMT2Ar label, which is years away at best.

NPM1m AML: Contested duopoly. Both approved within weeks (Oct 24 vs Nov 13, 2025). This is where the competitive dynamics are genuinely uncertain.

Syndax's advantages: ≈3-week head start, 1,050+ cumulative patients treated, 97% formulary coverage already in place from KMT2Ar launch, >80% of top accounts prescribing, broadest label (adults + pediatrics vs adults only for Komzifti), extensive combination data (40% of patients on combo therapy, per management Q4 call), NCCN guideline recommendation.

KURA's advantages: no QTc prolongation boxed warning (Revuforj's QTc black box is the single biggest competitive vulnerability — 36% overall incidence, 46% in elderly >65, QTcF >500msec in 10% of patients), once-daily dosing without required azole dose adjustments, and most importantly, cost: ≈$600K/year vs ≈$1M/year for Revuforj per IPD Analytics (independent payer consulting firm, cited on KURA Q4 2025 call), a ≈40% discount driven by Revuforj's "different dosing schemas [and] SKUs" requiring azole dose adjustments and multiple tablet strengths.

The step edit problem. KURA reported on their Q4 2025 earnings call that certain Blue Cross plans have implemented step edits requiring patients try Komzifti before Revuforj in adult NPM1m AML. Independent consultant IPD Analytics recommended this based on cost predictability, safety profile (no QTc), and combinability. KURA achieved 84% private payer coverage without additional restrictions within 90 days of launch.

Syndax management's response on the Q4 call: "Can't say felt much impact. Great fourth quarter relative competitor. Expect to dominate space. Superior product profile." This is the widest gap between management rhetoric and observable reality in the entire coverage. Management claims "superior product profile" against a competitor with no QTc boxed warning, 40% lower cost, once-daily dosing without azole adjustments, and independent consultant recommendations for formulary preference. Either management is seeing private data (prescriber switching, market share) that contradicts the structural economics, or they're not engaging honestly with the competitive threat.

Step edit scenario quantification. KURA achieved 84% private payer coverage in 90 days. If IPD Analytics recommendations spread and 30-50% of private payers implement step edits requiring Komzifti first in adult NPM1m AML:

• At 30% step edit adoption: SNDX retains ≈60% NPM1m share (academic centers override step edits; community follows them)
• At 50% step edit adoption: SNDX NPM1m share caps at ≈45-50%
• Impact on Revuforj peak: NPM1m revenue range narrows from $160-280M to $130-220M, a $30-60M annual headwind at peak
• KMT2Ar revenue ($200M) is unaffected — no competitor, no step edits

KURA's financials provide context: $0.8B market cap (vs SNDX $2.1B), $667M cash, $2.1M preliminary revenue (5 weeks of sales), and a Kyowa Kirin global partnership that funds development and ex-US commercialization. The street sees more upside in KURA: analyst mean target implies +246% upside vs +64% for SNDX. KURA is priced as higher risk (IV 104% vs SNDX 54%) but also higher reward. The market isn't saying KURA is definitively weaker — it's saying KURA is less proven but with more room to re-rate.

cGVHD: Niktimvo vs Established Therapies

Niktimvo is winning its market. $152M US net revenue (Incyte-reported) in 11 months, tracking ahead of Sanofi's REZUROCK at the same stage of launch. REZUROCK reached ≈$500M in peak annual sales within 4 years. 90% of BMT centers have prescribed Niktimvo, all with repeat orders. 60-70% patient persistency at 10 months.

The competitive moat is mechanistic: Niktimvo is the only CSF-1R antibody approved for cGVHD, the only therapy targeting both fibrosis and inflammation. It occupies a differentiated position in the treatment algorithm rather than substituting for existing therapies. No direct CSF-1R competitor is in late-stage development.

IPF: The Unpriced Option

Axatilimab is in a Phase 2 trial (MAXPIRe) for idiopathic pulmonary fibrosis, a ≈$4B market currently served by Ofev (nintedanib) and Esbriet (pirfenidone). Enrollment completed January 2026. Topline data expected H2 2026.

IPF is a graveyard for drug candidates — historical Phase 2 to Phase 3 success rates run 20-30%. But axatilimab has differentiated translational evidence: in cGVHD patients with bronchiolitis obliterans syndrome (a fibrotic lung condition), nearly 50% showed lung response at the lowest dose, with 90% symptom improvement. This is preclinical-to-clinical bridging evidence that most IPF candidates lack.

Counterparty validation: Royalty Pharma's CIO explicitly stated that IPF upside was "NOT in base case" for their $350M investment. Incyte is co-funding the trial. Neither counterparty has priced IPF success into their Niktimvo economics.

Management & Governance

CEO Michael Metzger has been with Syndax since 2015 (COO), CEO since February 2022. Previously CEO of Regado Biosciences (merged, eventually sold to Allergan) and COO of Mersana Therapeutics. MBA from NYU Stern.

CMO Nicholas Botwood replaced Neil Gallagher in May 2025 — a significant C-suite transition during the dual-launch period. Botwood came from BMS (SVP Head of Worldwide Medical Oncology) and AstraZeneca (Head of Oncology Clinical Development). Imperial College London, Fellow of the Royal College of Physicians. This is a material upgrade in registration-trial capability, which matters for the frontline AML and IPF programs.

Insider ownership: 39.1% held by executive officers, directors, and 5%+ holders. This is significant alignment. Recent transactions (Feb 2026) were routine post-award tax withholding sales — CEO sold 24,571 of 217,600 shares awarded (≈11%). No open market purchases (code P) detected. The absence of buying isn't surprising at 52-week highs, but it's not a bullish signal either.

Board: 7 members including Keith Katkin (former CEO of Avanir, sold to Otsuka) and Chairman Dennis Podlesak (in seat since 2008). Mix of operational, medical, and scientific expertise.

Capital allocation track record: The Vitae license (which produced Revuforj) was a transformative decision. The Incyte collaboration gave commercial scale without building global infrastructure. The Royalty Pharma deal is the most debatable — $350M non-dilutive at a critical moment, but the 13.8% perpetual royalty (capped at $822.5M) could prove expensive if Niktimvo reaches peak. The decision not to pursue M&A is an underrated positive. Headcount discipline (298 → 277 while launching two drugs) reinforces the capital allocation story.

Dilution: 88.2M shares outstanding. 30.3M reserved shares (options, RSUs, ATM program, ESPP) represent 35% potential dilution. Annual auto-increase of 4% adds ≈3.5M shares/year to the equity plan. SBC runs ≈$50M/year. At current prices, realized dilution is ≈2% annually, but the overhang from the ATM program ($175M remaining capacity) is the backstop management would use if the revenue trajectory disappoints.

Factor Profile

Factor regression (250-day, 3-factor: SPY + MTUM + XBI):

SNDX is 67% company bet, 33% biotech sector bet. This is below the 75% idiosyncratic variance target. XBI β of 1.52 is the dominant non-idiosyncratic factor — this is a 1.5x leveraged biotech position with company-specific alpha layered on top. Market beta and momentum are negligible.

Return attribution (1Y: +87.2%):

XBI component:    +65.4%  (75% of total return)
Alpha component:  +29.5%  (34% of total return)
SPY component:     -2.1%
MTUM component:    -5.5%

Three-quarters of the +87% return was biotech sector beta. XBI returned +48% over the period; with a 1.52 beta, SNDX mechanically captured 65 percentage points of return just from riding the sector. An investor who bought 1.5x XBI on margin would have captured 72% of SNDX's return with zero company-specific research.

The alpha IS real. The KURA comparison confirms this: nearly identical XBI beta (1.57), but negative alpha (-13.1%). Same sector exposure, opposite company-specific outcomes. After stripping XBI, the SNDX-KURA residual correlation is 0.259 — a menin inhibitor sub-factor exists but is modest.

Rolling profile is deteriorating. The 6-month window showed 74.6% idio (near target), but the last 3 months dropped to 54.1% — the stock is becoming more correlated with biotech as it rallies, not less.

Edge audit: We have edge in the idiosyncratic component (revenue inflection, competitive dynamics, IPF catalyst). We have no edge in XBI. The 35.7% of variance from biotech sector is unintentional beta. If XBI drops 20%, SNDX mechanically drops ≈30% regardless of fundamentals.

Style factor correlations (SMB, VLUE, QUAL) are all low (0.22-0.33). No meaningful value, quality, or size loading.

Forward Expectations Gap Analysis

What the Street Expects

Price targets: mean $39.18 (+64%), median $38, range $28-$57. 12 analysts, 100% bullish.

What Current Price Requires

At $2.06B EV, the stock trades at 5.7x 2026E consensus revenue ($363M) and 3.7x 2027E ($549M). For a commercial biotech growing 111% with 80%+ gross margins, this is a reasonable-to-cheap multiple. Peers with similar growth profiles trade 6-10x forward revenue.

Current price requires: continued 10-15% QoQ revenue growth on existing products, Niktimvo profit share scaling with SG&A leverage, losses narrowing but profitability not achieved in 2026, no major competitive disruption.

Current price does NOT require: IPF success, frontline AML approval, myelofibrosis entry, an acquisition premium, or Niktimvo reaching REZUROCK-level peak sales.

Peak Revenue Scenarios (R/R Products Only, No Pipeline)

Derivation of inputs:

Revuforj: KMT2Ar AML = ≈3,000-4,000 treatable US patients/year × ≈50% penetration × ≈$200K avg revenue per patient (shorter duration in R/R) = ≈$200M base. NPM1m AML = ≈5,000-6,000 treatable US patients × market share × similar pricing. KURA sizes the NPM1m R/R TAM at $350-400M total (both players). SNDX share depends on step edit dynamics: bull 70% ($245-280M), base 55% ($190-220M), bear 40% ($140-160M).

Niktimvo to SNDX: Incyte-reported US net revenue at peak (REZUROCK comp $500M floor per Incyte CEO, upside to $600M+) × SNDX effective take rate (28% today, improving toward 30-35% as SG&A leverages).

OpEx at scale: R&D normalizes to ≈$120-150M (fewer trials post-approval), SG&A stabilizes at ≈$120-140M. Total ≈$250-280M. COGS at 15-17% of combined revenue.

Current price ($23.88) sits between the time-discounted bear and base cases on R/R products alone. IPF is pure optionality on top. Note: these peak scenarios assume 3.5 years to maturity; the time discount at 12% reduces terminal values by ≈35%.

Five Disconnects

1. Gross margin compression is not modeled. Revuforj's 94.4% gross margin is temporary — the 10-K confirms COGS includes both manufacturing and AbbVie royalties, and current COGS is artificially low because pre-launch inventory (expensed as R&D) is being sold at near-zero manufacturing cost. As this depletes and $32.8M of full-cost inventory replaces it, COGS/revenue will rise from 5.6% to 15-17%, compressing gross margin to ≈83%. At $200M revenue, that's ≈$15-20M less gross profit than models carrying 94.4% forward.

2. Profitability timeline is slipping. FY2027 EPS consensus was +$0.06 sixty days ago. It is now -$0.16. The street is pushing out profitability despite stable revenue estimates. Meanwhile, management told JPM in January that they "expect to reach profitability" without the standard 12-month qualifier — more aggressive language than their own 10-K. Someone is wrong.

3. Q4 2025 miss was structural, not one-time. EPS of -$0.78 vs -$0.58 expected (-34.9% miss) after beating 3 of 4 prior quarters. The miss was driven by working capital dynamics ($32.8M inventory build, $30M AR increase, $43M collaboration receivable) and the inherently lumpy nature of the Niktimvo profit share, which depends on Incyte's cost allocation quarter to quarter. This will cause continued estimate volatility.

4. NPM1 "domination" vs payer step edits. Management claims minimal competitive impact from Komzifti and expects to "dominate" the NPM1 space. Payer step edits requiring Komzifti before Revuforj, driven by a 40% cost advantage and cleaner safety profile, create a ceiling management hasn't acknowledged. The question isn't whether Revuforj is the better drug (it may well be); it's whether payers will force a cheaper alternative first.

5. IPF is worth $4-8/share at zero in the price. Phase 2 topline H2 2026. Historical IPF success rates are 20-30%, but axatilimab's cGVHD anti-fibrotic data provides differentiated translational evidence.

IPF option value math:

Peak IPF revenue (if approved):     $400-800M (10-20% of $4B TAM)
Revenue multiple for growth pharma: 4-5x
Incremental EV if approved:         $1.6-4.0B
P(Phase 2 success → eventual approval): 25-35%
  (base rate 20-30%, adjusted up for cGVHD translational evidence)
Time discount (5yr to approval, 12%): 0.57
Probability-weighted PV:            $1.6B × 0.30 × 0.57 = $274M  (low end)
                                     $4.0B × 0.35 × 0.57 = $798M  (high end)
Per share (88.2M shares):            $3.10 - $9.05
Midpoint:                            ≈$6/share (25% of current price)

This is asymmetric: positive Phase 2 data would rerate the stock by $10-15/share on a single day (the market would price the conditional probability of eventual approval at 50%+ on good data). Negative data removes an option that was never priced — limited downside, perhaps a day of selling as the narrative loses a growth vector.

Counterparty Validation

Three counterparties. All independently bullish. None raising red flags.

Incyte is arguably more bullish on Niktimvo than Syndax itself. CEO William Meury called REZUROCK's ≈$500M annual sales the "low watermark" (floor) for Niktimvo. CCO Mohamed Issa: "Conceivable... several hundred million dollars annual sales 2028." Multiple executives described Niktimvo as "one of highest-margin products" in their portfolio — despite sharing 50% of profits with Syndax. Incyte is investing in two frontline combination trials, a subcutaneous formulation, and has made Niktimvo one of seven key growth drivers for their post-Jakafi-patent (2029) strategy.

Royalty Pharma committed $350M for a 13.8% perpetual US royalty, targeting "low double-digit IRR" over a "late 2030s" duration. Their 10-K provides an auditor-verified data point: they reversed their credit loss provision on Niktimvo in 2025, confirming that sell-side consensus forecasts improved during the first year of launch. Their CIO explicitly noted IPF and earlier-line GVHD were "NOT in base case."

AbbVie has zero mentions of revumenib, Revuforj, Syndax, or Vitae across 7+ earnings calls and their 10-K. At ≈$2-15M/year in royalties on $58B+ revenue, the obligation is a rounding error. No strategic interference risk.

Key Risks

Competitive erosion in NPM1m AML. Payer step edits favoring Komzifti's 40% lower cost and cleaner safety profile (no QTc boxed warning) could cap NPM1m market share at 50-60%. QTc prolongation at 46% in elderly patients (>65 years) is particularly problematic for a disease affecting primarily older adults. Fatal adverse reactions at 4% (9/241 patients, including 4 sudden deaths) may limit community oncology adoption.

Gross margin cliff. 94.4% → ≈83% as pre-launch inventory depletes. This is a known mathematical certainty, not a risk — it's just a question of timing and whether it's in models.

Royalty Pharma put right. $822.5M forced repurchase if UCB license terminates. Low probability, existential magnitude. With $394M cash, this would require immediate dilutive financing.

Biotech sector beta. XBI β of 1.52 means ≈35% of variance is unintentional sector exposure. A 20% XBI drawdown mechanically takes SNDX down ≈30% regardless of fundamentals. The rolling factor profile is worsening (idio% dropping from 75% to 54% in recent months).

Profitability timing. True FCF breakeven requires ≈$380-400M revenue (including working capital drag). Street consensus ($363M for 2026) falls short of this threshold. The Q4 miss and slipping FY2027 EPS estimates suggest the cost side is harder to model than it appears. If revenue stalls below $300M, cash burn resumes at $50-100M/year with $394M remaining. Additionally, positive IPF Phase 2 data — the primary bullish catalyst — would trigger Phase 3 investment, pushing OUT profitability even as it re-rates the stock. Success and profitability pull in opposite directions on the near-term cost structure.

Regulatory capacity. The 2025 10-K explicitly calls out FDA DOGE-era layoffs as a risk to regulatory capacity — the most specific government risk language in any Syndax filing. Material for a company with four-plus active regulatory submissions (EVOLVE-2, REVEAL-ND, RAVEN, IPF).

Dilution. 30.3M reserved shares (35% potential dilution). 4% annual auto-increase to equity pool. $175M remaining ATM capacity. SBC at $50M/year. If revenue disappoints and the ATM is tapped, dilution accelerates.

Customer and supplier concentration. Four customers represent 92% of accounts receivable and net product sales. Single-source API suppliers. All manufacturing outsourced to CMOs. Standard for specialty oncology but presents supply disruption risk.

Milestone outflow acceleration. >$780M in remaining milestone obligations to AbbVie, UCB, and Bayer. These trigger as revenue grows — the more successful the company, the more cash flows out. The street may model revenue without fully burdening for the royalty and milestone stack.

What to Watch

Q1 2026 earnings (May 4, 2026). Street expects revenue of $73M, EPS of -$0.55. The key isn't the headline — it's NPM1m patient share trends vs Q4's 30% of new starts, and any management commentary on payer step edits. If they continue to dismiss the Komzifti competitive threat while KURA reports step edit momentum, the gap between rhetoric and reality widens.

Revuforj COGS trajectory. Watch gross margin quarter by quarter. The shift from 94.4% toward ≈83% will be visible in COGS line growth outpacing revenue growth. When this shows up is when the pre-launch inventory is fully depleted.

IPF Phase 2 topline (H2 2026). Binary catalyst. Positive data = massive re-rate into a $4B market. Negative data = minor hit (not priced in). This is the most important event in 2026 for the stock.

Niktimvo profit share take rate. Track the ratio of SNDX collaboration revenue to Incyte-reported Niktimvo net revenue each quarter. Currently 28%. If this moves toward 30-35%, the economics are leveraging as management guides. If it stays flat or declines, the cost structure is stickier than expected.

KURA Komzifti launch metrics. KURA's quarterly revenue disclosures will reveal the pace of NPM1m market share erosion. Watch prescriber share data, payer coverage updates, and any additional step edit announcements.

XBI sector correlation. If you hold SNDX, you're holding 1.5x biotech. Monitor whether the factor loading continues to increase (last 3mo: 54% idio, down from 75% at 6mo). If the stock becomes more of a sector bet, the thesis needs a sector view to justify unhedged exposure.

Frontline AML trial enrollment. EVOLVE-2 (unfit NPM1m) and REVEAL-ND (fit NPM1m) are enrolling. The frontline TAM ($5B+) dwarfs R/R. Enrollment pace and any interim data signals will indicate timing and probability of label expansion.

Insider activity. Watch for code P (open market purchases) — none detected to date. Management selling beyond routine tax withholding would be a negative signal. Buying would be meaningfully bullish at these levels.

LR Signal: 1.3

This is a subjective synthesis, not a mathematical aggregation of the 40 evidence items. The evidence table contains strong bearish signals (step edits at LR 0.5, QTc at 0.6, margin compression at 0.6-0.7) and strong bullish signals (IPF option at 1.5, Incyte bullishness at 1.3-1.5, RPRX provision reversal at 1.4). A naive product of all LRs would be dominated by the bearish items and land below 1.0. The 1.3 reflects a judgment that:

1. The IPF free option (≈$6/share midpoint at zero in the price) is the primary bullish divergence, and it's supported by both clinical evidence (cGVHD lung response) and counterparty validation (RPRX and Incyte explicitly excluding it from base cases)
2. The competitive risk from Komzifti is real but bounded — KMT2Ar is a monopoly, and even with step edits NPM1m share likely stays >45%
3. The gross margin compression is a mathematical certainty but is a ≈$15-20M headwind, not thesis-breaking
4. The 28.7% short interest cuts both ways: sophisticated investors are betting against the stock at $24, which should temper bullishness, but the 17.6 days to cover creates mechanical squeeze risk if any catalyst hits

Net: modestly underpriced relative to the evidence, driven primarily by unpriced IPF optionality. But the 1.52x XBI beta means ≈35% of any position is an unintentional biotech sector bet where you have no edge, and the stock is technically stretched (RSI 74, 94% of 52-week range) with nearly 30% of the float sold short.

Evidence